...BRCA1, BRCA2, BARD1, PALB2, TP53, CHEK2). Lipid-based nanoparticles (LNPs) and polymeric nanoparticles (PNPs) were devel...
...BRCA1, BRCA2 and TP53, which are associated with chemotherapy sensitivity. Olaparib, a PARP inhibitor, provides the grea...
...BRCA1/2 carrier screening in July 2022. This observational study assesses the effectiveness of the intervention in encou...
...BRCA1/2-mutant tumors, toxicity and limited tumor-selective exposure often restrict its impact. To address these barrier...
...BRCA1, and C/EBPβ. On the other hand, miR-181a and miR-214-5p contribute to resistance by upregulating STING and downreg...
...BRCA1/2 pathogenic variant detection, 99% for hormone receptor status, 96% for HER2 status, 91% for clinical stage, 91% ...
...BRCA1/2)-mutated breast cancer. Their inhibition exemplifies synthetic lethality and has shown clinical efficacy. Four P...
...BRCA1/2 and homologous recombination deficiency status), genomic signatures (e.g. Oncotype DX) and ultimately the patien...
...BRCA1/2 or PALB2 mutations (n = 29) and an exploratory cohort of patients who were either HER2-negative with other DDR m...
...BRCA1 and BRCA2 was statistically significant (p-value<0.001). There was no indication of publication bias in BRCA1 (Egg...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
